Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns Orphan Drug Designation from FDA for Small-Cell Lung Cancer

Fineline Cube Aug 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company

Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs

Fineline Cube Aug 9, 2024

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its...

Company Legal / IP

Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement

Fineline Cube Aug 9, 2024

Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...

Company Deals

WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors

Fineline Cube Aug 9, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...

Company

Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024

Fineline Cube Aug 9, 2024

Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has...

Company Deals

AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million

Fineline Cube Aug 9, 2024

Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered...

Company

Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands

Fineline Cube Aug 9, 2024

Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately...

Company Drug

Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment

Fineline Cube Aug 8, 2024

Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...

Company

BeiGene’s Q2 2024 Revenues Surge 56% YOY, Highlighted by Strong U.S. Market Performance

Fineline Cube Aug 8, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has reported its financial results for the second...

Company

Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development

Fineline Cube Aug 8, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results...

Policy / Regulatory

NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs

Fineline Cube Aug 8, 2024

The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have...

Company Digital R&D

Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration

Fineline Cube Aug 8, 2024

Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with...

Company Deals Hospital

Hygeia Healthcare Holdings Acquires Chang An Hospital in Deal Valued at RMB 1.66 Billion

Fineline Cube Aug 8, 2024

Hygeia Healthcare Holdings Co., Ltd, a Shanghai-based medical investment and healthcare group, has announced the...

Company Drug

Changshan Biochemical Gets Marketing Nod for Enoxaparin in Kyrgyzstan for Venous Thromboembolic Diseases

Fineline Cube Aug 8, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Drug

Haisco Pharmaceutical’s PDE4B Inhibitor HSK44459 Gets NMPA Green Light for Interstitial Lung Disease Clinical Trial

Fineline Cube Aug 8, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...

Company Medical Device

Vazyme Biotech Secures NMPA Nod for Two RSV Antigen Detection Kits

Fineline Cube Aug 8, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), a biotechnology company based in China, has announced that...

Company Deals

Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer

Fineline Cube Aug 8, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S....

Company Drug

Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment

Fineline Cube Aug 8, 2024

The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a...

Company

Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025

Fineline Cube Aug 8, 2024

Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second...

Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma

Fineline Cube Aug 7, 2024

Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...

Posts pagination

1 … 362 363 364 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.